CALL US

Tel: +39.0523.315144 | Fax: +39.0523.1860018

EMAIL US
OPENING HOURS

Mon - Fri: 10 am - 4 pm

Disclaimer
ESSIC endeavours to ensure that all information it provides is correct and accurate, but does not accept any liability for errors or inaccuracies.

ESSIC does not necessarily endorse any commercial products mentioned on its website or in any other information material it publishes.

© 2018 by ESSIC

GENERAL APPROACH TO TREATMENT

ORAL TREATMENT | Double-blind randomized placebo-controlled studies

 

  • Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis
    Nickel JC, Barkin J, Forrest J, et al. Urology 2005;65:654-8
    • three dosages (300, 600, and 900 mg) of PPS in a randomized, double-blind, double-dummy, parallel-group, multicenter, 32-week study were studied in 380 IC patients
    • at study end, 27.5%, 56.9%, and 15.7% reported mild, moderate, and severe symptoms, respectively
    • for all three dosages of PPS, a clinically significant but similar response was demonstrated; the duration of therapy appears to be more important than the dosage

  • Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis
    Warren JW, Horne LM, Hebel JR, et al. J Urol 2000;163:1685-8
    • 50 patients with IC were randomized to receive 18 weeks of placebo or antibiotics, including rifampin plus a sequence of doxycycline, erythromycin, metronidazole, clindamycin, amoxicillin and ciprofloxacin for 3 weeks each. 
    • 12 of 25 patients (48%) in the antibiotic and 6 of 25 (24%) in the placebo group reported overall improvement (p = 0.14), while 10 and 5, respectively, noticed improvement in pain and urgency (p = 0.22). 
    • in the antibiotic group 20 participants (80%) had adverse effects compared with 10 (40%) in the placebo group (p = 0.009). 
    • the authors conclude that their findings suggest that these antibiotics alone or in combination may sometimes be associated with decreased symptoms in some patients but they do not represent a major advance in therapy for interstitial cystitis

  • A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease
    Holm-Bentzen M, Jacobsen F, Nerstrom B, et al. J Urol 1987;138:503-7 
    • protocol A included 43 patients with clinically and pathologically anatomically verified interstitial cystitis (28 or more mast cells per mm.2) 
    • protocol B included 72 patients with a painful bladder and unspecific histological findings 
    • patients were randomized to receive either sodium pentosanpolysulfate (200 mg. twice daily) or placebo capsules for 4 months 
    • before and after the trial the patients were evaluated with symptom grading, urodynamics and cystoscopy with distension and deep bladder biopsies 
    • the results showed no difference between the pre-trial and post-trial values in the sodium pentosanpolysulfate and placebo groups in both protocols in regard to symptoms, urodynamic parameters, cystoscopic appearance and mast cell counts. 
    • a significant increase in the cystoscopically determined bladder capacity in the sodium pentosanpolysulfate group in protocol A was found 
    • the authors conclude that no statistically or clinically significant effect of sodium pentosanpolysulfate was found compared to placebo in patients with painful bladder disease

 

Open studies and non-placebo-controlled studies

 

 

Case Reports

 

INTRAVESICAL TREATMENT

 

  • Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product
    Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Scand J Urol Nephrol 2005;39:143-7 
    • in this prospective, unblinded, uncontrolled pilot study, 20 patients with IC/PBS received weekly bladder instillations of hyaluronic acid for 1 month and monthly instillations for a further 2 months
    • patients were then offered further monthly instillations and all were subsequently evaluated after 3 years 
    • patient outcomes assessed were urinary frequency, use of analgesics and pain 
    • the authors conclude that hyaluronic acid safely reduced the pain and, to lesser degree, the urinary frequency associated with IC

Case Reports

  • [Intravesical instillation of resiniferatoxin for the patients with interstitial cystitis] [article in Japanese] 
    Takahashi S, Yanase M, Inoue R, et al. Hinyokika Kiyo 2006;52:911-3 
    • resiniferatoxin (RTX) treatment was given to 3 patients with incomplete improvement after hydrodistention; all 3 patients were free of bladder pain posttreatment and had slight improvement of the maximum voided volume
    • the authors conclude that although RTX treatment required general anaesthesia against severe bladder pain it is effective for selected IC patients

Reviews

NEUROMODULATION TREATMENT

  • Bilateral s3 stimulator in patients with interstitial cystitis
    Steinberg AC, Oyama IA, Whitmore KE. Urology 2007;69:441-3
    • this retrospective study demonstrated that 15 patients diagnosed with interstitial cystitis with the symptoms of frequency, urgency, and pain had a significant decrease in frequency and nocturia with bilateral stimulator placement

SURGICAL TREATMENT (UNDER CONSTRUCTION)

OTHER TREATMENT

Hyperbaric oxygen

 

Hydrodistension

 

OVERVIEW OF RANDOMIZED-CONTROLLED TRIALS WITH BENEFICIAL EFFECT

Oral treatment

  • Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis
    Nickel JC, Barkin J, Forrest J, et al. Urology 2005;65:654-8
    • three dosages (300, 600, and 900 mg) of PPS in a randomized, double-blind, double-dummy, parallel-group, multicenter, 32-week study were studied in 380 IC patients
    • at study end, 27.5%, 56.9%, and 15.7% reported mild, moderate, and severe symptoms, respectively
    • for all three dosages of PPS, a clinically significant but similar response was demonstrated; the duration of therapy appears to be more important than the dosage

 

Intravesical treatment

  • Safety and Efficacy of the Use of Intravesical and Oral Pentosan Polysulfate Sodium for Interstitial Cystitis: A Randomized Double-Blind Clinical Trial
    Davis EL, El Khoudary SR, Talbott EO, et al. J Urol 2007 Nov 12; [Epub ahead of print]
    • 41 females diagnosed with IC were randomized to receive a combination of intravesical pentosan polysulfate sodium plus oral pentosan polysulfate sodium or intravesical placebo plus oral pentosan polysulfate sodium for 6 weeks; all subjects continued to receive oral pentosan polysulfate sodium for another 12 weeks
    • at week 18 the treatment group showed statistically significant improvement in all quality of life scores, while the placebo group showed significant improvement in only 3 quality of life scores compared to the baseline

TREATMENT OF BPS